Originally posted by Few Pennies
Wasa
Because the trials etc take so long, people simply become bored with IMU many have held this share for a really long time and as a result have just simply become tempted to sell, this in my view is why the price is held low ( I don't buy the idea expressed by a few on this forum that its mostly caused by manipulation but I admit that could sometimes be the case, but I think all in all we give too much belief in the manipulation idea than is actually reality)
That being said, as I see that the fundamentals as outlined over the last three years
in any of the announcements, Imugene has it seems to me to only have strengthened and substantially de-risk this technology.
Really hoping and expecting it will be good news that Leslie brings (as previously indicated) sometime this month.
It would be a real bummer for my overweight holding if Imugene decide due to bad results to shut the whole thing down.
That being said, my view is still positive,and when, I get the jitters (which with an early stage Bio tech investment is only natural) I go back and re-read and scrutinise Imugene's announcements, doing this reminds me and helps me remember why I invested here in the first place.
the only caveat to re-reading those old announcements however is, not only do they give me back my confidence to hold I usually find myself unable to resist buying more, (even got a few more last week at 2.3 cents )and as a result by some measures, some might say I have ended up a little overweight in this stock.
fp
LoL fp, at 2.3c last week you probably bought mine.
That’s nothing to what GSK spent on Tesaro last week, $5.1b deal!
https://www.fiercepharma.com/pharma...up-new-favorite-oncology-buys-tesaro-for-5-1b
I was thinking IMU would turn out to be the next CSL, but after Paul’s interview, I felt slightly disappointed that we’re only after a VLA style buy out. On the other hand, I can see how this can possibly play out:
Back in April, after getting positive initial trial results, Axel recommended the board to buy out other B-cell vaccine trials (OSU/Mayo) to ensure IMU monopolise B-cell vaccines with the view of one day being bought by GSK.
We are a research arm of GSK but At the moment it’s cheaper & less risk for them to let Imugene stays as an independent company to do the trials.
If the vaccine works & in combo with the anti PD1 etc, can be produced at cheaper cost than the competitors & we are the only one in the game, you’d think multi billion $ reward is waiting if the trials are successful.
Anyway, just a wishful thinking..
(20min delay)
